Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.91B | $2.89B | $3.07B | $3.07B | $3.27B | $4.76B | $4.41B | $4.42B | $4.44B | $4.71B |
| Revenue growth | — | -0.8% | 6.2% | 0.1% | 6.6% | 45.6% | -7.4% | 0.1% | 0.5% | 6.2% |
| Gross profit | — | — | — | — | — | — | — | $2.49B | $2.44B | $2.59B |
| Gross margin | — | — | — | — | — | — | — | 56.3% | 54.9% | 55.0% |
| Net income | -$47.9M | -$311M | $86.5M | $68.0M | -$574M | -$483M | -$78.0M | -$1.23B | $338M | -$232M |
| Net margin | -1.6% | -10.8% | 2.8% | 2.2% | -17.5% | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
| EPS (diluted) | -$0.16 | -$1.06 | $0.28 | $0.18 | -$1.30 | -$0.99 | -$0.16 | -$2.50 | $0.68 | -$0.47 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $156M | $174M | $487M | $224M | -$41.0M | $483M | $452M | $271M | $541M | $560M |
| Capital expenditures | $110M | $98.6M | $135M | $140M | $135M | $159M | $171M | $140M | $147M | $276M |
| Free cash flow | $45.6M | $75.2M | $353M | $84.0M | -$176M | $324M | $281M | $131M | $394M | $284M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $259M | $323M | $475M | $334M | $495M | $638M | $345M | $352M | $468M | $545M |
| Total assets | — | $8.94B | $8.96B | $8.99B | $17.7B | $16.5B | $15.5B | $14.4B | $12.6B | $13.4B |
| Total liabilities | — | $1.16B | $3.76B | $3.44B | $9.22B | $8.97B | $8.20B | $8.14B | $6.52B | $6.81B |
| Long-term debt | — | $0.00 | $2.47B | $2.35B | $6.13B | $6.32B | $5.84B | $5.77B | $4.32B | $3.76B |
| Shareholders' equity | $7.02B | $7.78B | $5.20B | $5.54B | $8.46B | $7.51B | $7.29B | $6.22B | $6.10B | $6.55B |
| Retained earnings | — | $0.00 | $16.4M | $84.3M | -$477M | -$979M | -$1.06B | -$2.29B | -$1.95B | -$2.18B |
| Shares (wtd avg diluted) | 293M | 293M | 314M | 370M | 441M | 487M | 488M | 492M | 497M | 496M |
Every figure is extracted from Elanco Animal Health Inc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.